Literature DB >> 10511409

Activity of moxifloxacin against mycobacteria.

S H Gillespie1, O Billington.   

Abstract

Moxifloxacin is an 8-methoxyquinolone compound with activity against a wide range of bacteria. We tested its activity in comparison with four other quinolones and isoniazid against clinical isolates of mycobacteria. It proved to be the most active of the quinolones tested against Mycobacterium tuberculosis (MIC90 0.25 mg/L), Mycobacterium avium-intracellulare (MIC90 1.0 mg/L), Mycobacterium kansasii (MIC90 0.06 mg/L) and Mycobacterium fortuitum (MIC90 1 mg/L). These data indicate that moxifloxacin merits further study as an antimycobacterial agent.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10511409     DOI: 10.1093/jac/44.3.393

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  35 in total

1.  New regimens for reducing the duration of the treatment of drug-susceptible pulmonary tuberculosis.

Authors:  Marcus B Conde; José R Lapa E Silva
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

2.  Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.

Authors:  Eric Nuermberger; Sandeep Tyagi; Kathy N Williams; Ian Rosenthal; William R Bishai; Jacques H Grosset
Journal:  Am J Respir Crit Care Med       Date:  2005-09-08       Impact factor: 21.405

Review 3.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 4.  Current prospects for the fluoroquinolones as first-line tuberculosis therapy.

Authors:  Howard Takiff; Elba Guerrero
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

5.  Higher Dosing of Rifamycins Does Not Increase Activity against Mycobacterium tuberculosis in the Hollow-Fiber Infection Model.

Authors:  E D Pieterman; S van den Berg; A van der Meijden; E M Svensson; H I Bax; J E M de Steenwinkel
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

6.  In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.

Authors:  Areeya Disratthakit; Norio Doi
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

7.  A Macrophage Infection Model to Predict Drug Efficacy Against Mycobacterium Tuberculosis.

Authors:  Kaitlyn Schaaf; Virginia Hayley; Alexander Speer; Frank Wolschendorf; Michael Niederweis; Olaf Kutsch; Jim Sun
Journal:  Assay Drug Dev Technol       Date:  2016-06-21       Impact factor: 1.738

8.  Functional characterisation of mycobacterial DNA gyrase: an efficient decatenase.

Authors:  U H Manjunatha; M Dalal; M Chatterji; D R Radha; S S Visweswariah; V Nagaraja
Journal:  Nucleic Acids Res       Date:  2002-05-15       Impact factor: 16.971

9.  Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen.

Authors:  Won-Jung Koh; Goohyeon Hong; Su-Young Kim; Byeong-Ho Jeong; Hye Yun Park; Kyeongman Jeon; O Jung Kwon; Seung-Heon Lee; Chang Ki Kim; Sung Jae Shin
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

10.  Combined effect of Neridronate and specific antibiotic therapy in a case of tuberculous spondylodiscitis.

Authors:  L Quarta; A Corrado; N Melillo; A Trotta; G Scotto; F d'Onofrio; N Santoro; F P Cantatore
Journal:  Rheumatol Int       Date:  2007-09-26       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.